企業プロフィール
Ascendis Pharma 株価・ニュース・カタリスト
- ティッカー:
- ASND
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Denmark
株価パフォーマンス
253.29 USD (-0.60%)
終値
最終更新: 2026年8月21日
13.4B USD
時価総額
株価変動の要因
As of Aug 21, 2026, ASND closed down 0.60% at $253.29. No new same-company headline was identified in the current news window.
企業概要
TransCon Technology
Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology.
Commercial Endocrinology Portfolio
YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA is a once-weekly growth-hormone therapy, and YUVIWEL is approved in the United States for children with achondroplasia.
Growth-Disorder Development
Ascendis is studying TransCon CNP in infants with achondroplasia and in hypochondroplasia. It is also evaluating TransCon CNP combined with TransCon hGH to address growth and skeletal complications.
Oncology Program
Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
今後のカタリスト
- European regulatory decision for YUVIWEL in the fourth quarter of 2026.
- Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026.
- Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。